CATALENT, INC. (NYSE:CTLT) Files An 8-K Financial Statements and Exhibits

0

CATALENT, INC. (NYSE:CTLT) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1 Press Release of Catalent, Inc., dated October16, 2017, announcing pricing of notes offering.

EXHIBIT LIST


Catalent, Inc. Exhibit
EX-99.1 2 d475881dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Catalent Announces Pricing of Private Offering of Senior Unsecured Notes Due 2026 SOMERSET,…
To view the full exhibit click here

About CATALENT, INC. (NYSE:CTLT)

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.